Abstract:BACKGROUND PD-1/PD-L1 blockade immunotherapies have changed the landscape of cancer therapy. However, the main limitation of these therapies is the lack of definitively predictive biomarkers to predict treatment response. Whether PD-L1 expression on circulating tumor cells (CTCs) is associated with the clinical outcomes of immunotherapy remains to be extensively investigated. METHODS 155 patients with different advanced cancers were enrolled in this study and treated with anti-PD-1/PD-L1 monoclonal antibodies (mAbs). Using the Pep@MNPs method, CTCs were isolated and enumerated. The PD-L1 expression levels were analyzed by an immunofluorescence assay for semiquantitative assessment with four categories (negative, low, medium and high). RESULTS Prior to immunotherapy, 81.93% (127/155) of patients had PD-L1-positive CTCs, and 71.61% (111/155) had at least one PD-L1-high CTC. The group with PD-L1-positive CTCs had a higher disease control rate (DCR) (71.56%, 91/127), with a DCR of only 39.29% (11/28) for the remaining individuals (P=0.001). The objective response rate (ORR) and DCR in PD-L1-high patients were higher than those in the other patients (32.44% vs 13.64%, P=0.018 and 75.68% vs 40.91%, P<0.0001, respectively). The reduction in the counts and ratios of PD-L1-positive CTCs and PD-L1-high CTCs reflected a beneficial response to PD-1/PD-L1 inhibitors. Furthermore, patients with PD-L1-high CTCs had significantly longer progression-free survival (PFS) (4.9 vs 2.2 months, P<0.0001) and overall survival (OS) (16.1 vs 9.0 months, P=0.0235) than those without PD-L1-high CTCs.Conclusions The PD-L1 level on CTCs may serve as a clinically actionable biomarker for immunotherapy, and its dynamic changes could predict the therapeutic response. IMPLICATIONS FOR PRACTICE This study was designed to investigate the role of PD-L1 expression on circulating tumor cells in predicting and monitoring response to PD-1/PD-L1 blockade immunotherapies in patients with advanced cancer. The results of the study showed that PD-L1-high expression CTCs were both a predictive biomarker and a prognostic factor in patients with advanced cancer treated with anti-PD-1/PD-L1 mAbs. These observations suggest that PD-L1 level on CTCs is a potential clinical biomarker for immunotherapy.

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

P34.02 Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: are we on the right path?

Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

PD-L1 Expression by Two Complementary Diagnostic Assays and Mrna in Situ Hybridization in Small Cell Lung Cancer.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer

Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab

Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.

Assessment of PD-L1 Expression in Circulating Tumor Cells in Patients with Breast Cancer.

Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer